PwPepwise

Livagen

Anti-Aging & Longevity

Liver-targeted bioregulator

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide originally developed as a bioregulator with potential applications in aging biology.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
General protocol——OralTaken by mouth.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide originally developed as a bioregulator with potential applications in aging biology and cellular health. It is composed of four amino acids and appears to act primarily by influencing how DNA is packaged within cells — a process known as chromatin remodeling. In early laboratory studies, Livagen has been reported to reverse age-associated tightening of chromatin in human lymphocytes, potentially reactivating genes that had been silenced over time1,2. This epigenetic activity may have broad implications for how cells function as they age.

Beyond its effects on chromatin structure, Livagen has been reported to show cytoprotective properties in cells exposed to chemical and radiation-induced stress2,3, and may support cellular homeostasis in liver tissue7. In animal studies, the peptide appears to exert age-dependent effects on digestive enzyme activity, normalizing levels in older animals toward those seen in younger ones4. Its resistance to degradation by intestinal enzymes also suggests it may remain biologically active following oral administration4. Human studies are actively emerging across several areas including cardiovascular-related genomic instability5 and oncology-adjacent cellular protection8, making Livagen a peptide of growing interest in the geroscience field.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Livagen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Ala (KEDA). It belongs to a class of short-chain peptide bioregulators originally developed within the Russian gerontological research tradition as tissue-specific cytoprotective agents. Its primary characterized molecular activity involves modulation of chromatin architecture — specifically the reversal of age-associated hyperheterochromatinization in somatic cells.

At the chromosomal level, Livagen has been reported to induce decondensation of pericentromeric structural heterochromatin in aged human lymphocytes, releasing genes that had been epigenetically silenced through age-related chromatin condensation1. This de-heterochromatinization process appears to include activation of ribosomal genes and reactivation of facultative heterochromatin-repressed loci1. Independent work suggests Livagen can differentially modulate pericentromeric versus telomeric heterochromatin regions, with the former being preferentially targeted by cobalt ion exposure and the latter more sensitive to Livagen-cobalt combination treatment, as measured by sister chromatid exchange (SCE) frequency2. These findings imply that Livagen may interact with or modulate chromatin-associated protein complexes governing condensation state, though the precise receptor targets or enzymatic intermediaries have not yet been fully characterized in the published literature.

Livagen has also been reported to increase nucleolar organizer region (NOR) activity in lymphocytes from patients with hypertrophic cardiomyopathy, suggesting a role in regulating ribosomal RNA gene transcription — a process directly tied to cellular biosynthetic capacity6. This NOR-activating property is consistent with its broader reported chromatin-activating profile.

From a pharmacokinetic standpoint, Livagen appears to be resistant to hydrolysis by small intestinal peptide hydrolases in vitro, suggesting the intact tetrapeptide may survive gastrointestinal transit4. In addition, Livagen reduced glycil-L-leucinedipeptidase activity in the small intestine by approximately 50% in vitro, and oral administration produced age-dependent bidirectional modulation of multiple digestive enzyme activities — suppressive in young rats and stimulatory in aged rats4. This bidirectional, normalizing pattern is consistent with a bioregulatory rather than pharmacologically unidirectional mechanism of action, and may reflect differential receptor sensitivity or downstream signaling pathway activity across age-differentiated cellular environments. Formal pharmacokinetic parameters including half-life, bioavailability, and metabolic pathways in humans are currently being characterized in ongoing research.

§04Evidence & efficacy

Evidence base
10Studies
7Human
2Animal

Livagen's most consistently reported activity across independent studies is chromatin remodeling in aged human lymphocytes. The peptide has been reported to induce decondensation of pericentromeric structural heterochromatin1, potentially reactivating genes silenced by age-related epigenetic changes. This deheterochromatinization effect appears to differentially target pericentromeric versus telomeric heterochromatin regions, particularly in combination with cobalt ions2.

In cytoprotection studies, Livagen has been reported to reduce cobalt chloride-induced chromosomal aberrations in aged lymphocyte cultures, decreasing aberration frequency from 4.2±0.7% to 3.4±0.6%2. The peptide has also been reported to modulate the cellular adaptive response to radiation in lymphocytes from elderly individuals aged 72–86 years3.

In the context of disease-associated genomic instability, Livagen has been reported to normalize chromosomal aberrations, aneuploidy, and polyploidy in lymphocyte cultures from atherosclerosis patients5, and to increase nucleolar organizer region (NOR) activity and acrocentric chromosome association frequency in lymphocytes from hypertrophic cardiomyopathy patients6. Similar protective effects on genomic parameters have been reported in ex vivo cultures from ductal breast cancer patients8.

In animal models, Livagen may restore digestive enzyme activity in aged rats toward levels observed in young animals4, and has been reported to support hepatocellular structural and functional homeostasis in organotypic liver culture7.

§05Safety

Published studies on Livagen do not report any observed adverse effects, toxic responses, or safety signals in any experimental context to date1,2,3,4,5,6,7,8. No clinical safety data from human subjects receiving systemic Livagen have been published. All human studies in the available evidence base used ex vivo or in vitro lymphocyte culture models, meaning participants were not directly administered the peptide1,2,3,5,6,8.

In the animal model employing oral administration, no safety concerns were reported over a two-week treatment period4. The peptide's resistance to hydrolysis by small intestinal peptide hydrolases4 suggests it is not rapidly degraded in the gut, which is relevant context for future tolerability assessment. In organotypic liver culture, Livagen appeared to support rather than disrupt hepatocellular structural integrity7.

No drug interactions, contraindications, or organ toxicity findings appear in any study. Formal Phase 1 human safety and tolerability data remain an area of active clinical development for this compound.

§06History

Livagen (Lys-Glu-Asp-Ala, or KEDA) was developed as part of a broader program of peptide bioregulator research pioneered largely by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, beginning in the late Soviet era and continuing through the 1990s and 2000s. This research program sought to identify short peptide sequences derived from organ-specific tissues that could serve as cytoprotective and gerontoprotective agents. Livagen was categorized within this framework as a peptide with activity relevant to lymphocyte biology and aging-associated epigenetic changes.

The first substantively characterized study of Livagen appeared in 2002, when Khavinson and collaborators in collaboration with Georgian researchers including Lezhava and Monaselidze demonstrated that the peptide induced chromatin activation in lymphocytes from elderly donors1. Concurrent work in organotypic liver culture also published in 2002 reported pro-regenerative hepatocellular effects7. Subsequent years saw an expanding research collaboration between Russian and Georgian groups, with studies through 2007 characterizing Livagen's effects on heterochromatin regions2 and radiation adaptive response in aged cells3. Animal studies published between 2002 and 2005 explored gastrointestinal enzyme modulation4.

From approximately 2014 onward, research interest expanded to disease-specific genomic instability contexts, including atherosclerosis5, hypertrophic cardiomyopathy6, and ductal breast cancer8. Livagen has not received regulatory approval as a therapeutic agent in major Western markets, and its development continues primarily within the Russian and Georgian gerontological research communities.

§07References